Sugi Predict

Sugi Predict / Compounds / SCHEMBL2322722

SCHEMBL2322722

SCHEMBL2322722

CCCC1CC(=O)N([C@@H](CC)C(=O)O)C1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ BRD4 O60885 3/20 0.38
▸ MAPT P10636 1/20 0.38
▸ MME P08473 1/20 0.38
▸ LMNA P02545 1/20 0.36
▸ CA12 O43570 1/20 0.36
▸ CA1 P00915 1/20 0.36
▸ CA2 P00918 1/20 0.36
▸ CA3 P07451 1/20 0.36
▸ CA4 P22748 1/20 0.36
▸ CA6 P23280 1/20 0.36
▸ CA5A P35218 1/20 0.36
▸ CA7 P43166 1/20 0.36
▸ CA9 Q16790 1/20 0.36
▸ CA13 Q8N1Q1 1/20 0.36
▸ CA14 Q9ULX7 1/20 0.36
▸ CA5B Q9Y2D0 1/20 0.36
▸ ACE P12821 1/20 0.35
▸ TSHR P16473 1/20 0.33
▸ FYN P06241 1/20 0.33
▸ MDM2 Q00987 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6869302 1.00 BRD4 (0.38) BRD4MAPTMMELMNACA12
SCHEMBL31030093 1.00 BRD4 (0.38) BRD4MAPTMMELMNACA12
SCHEMBL16223981 1.00 BRD4 (0.38) BRD4MAPTMMELMNACA12
SCHEMBL31030092 1.00 BRD4 (0.38) BRD4MAPTMMELMNACA12
SCHEMBL2322732 1.00 BRD4 (0.38) BRD4MAPTMMELMNACA12
SCHEMBL2329044 1.00 BRD4 (0.38) BRD4MAPTMMELMNACA12
SCHEMBL22129282 1.00 BRD4 (0.38) BRD4MAPTMMELMNACA12
SCHEMBL22426199 1.00 BRD4 (0.38) BRD4MAPTMMELMNACA12
SCHEMBL22231243 1.00 BRD4 (0.38) BRD4MAPTMMELMNACA12
SCHEMBL5012986 0.91 ACE (0.43) BRD4MAPTMMEACETSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-114634437-A Simple preparation method of brivaracetam 武汉氟本氘合新材料科技有限公司 2022-06-17 — — CN claimed
CN-113582902-B Preparation method of buvaracetam and intermediate thereof 浙江华海药业股份有限公司 2025-02-28 — — CN disclosed
CN-113582902-B Preparation method of buvaracetam and intermediate thereof 浙江华海药业股份有限公司 2025-02-28 — — CN disclosed
EP-4282971-A1 AN IMPROVED PROCESS FOR THE PREPARATION OF (R )-4-PROPYL PYRROLIDINE-2-ONE, A KEY INTERMEDIATE FOR SYNTHESIS OF BRIVARACETAM Divi's Laboratories Limited (IN) 2023-11-29 — — EP disclosed
US-20230373914-A1 PROCESS FOR THE PREPARATION OF (R)-4-PROPYL PYRROLIDINE-2-ONE, A KEY INTERMEDIATE FOR SYNTHESIS OF BRIVARACETAM DIVI'S LABORATORIES LTD. (IN) 2023-11-23 — — US disclosed
EP-4036244-B1 ENZYMATIC PROCESS FOR THE PREPARATION OF (2S)-2-[(4R)-2-OXO-4-PROPYL-PYRROLIDIN-1-YL]BUTYRIC ACID AND ITS CONVERSION INTO BRIVARACETAM DIVIS LABORATORIES LTD (IN) 2023-10-11 — — EP disclosed
US-11673862-B2 Processes to produce brivaracetam SUZHOU PENGXU PHARMATECH CO. LTD. (CN) 2023-06-13 — — US disclosed
US-20230174478-A1 METHOD FOR PREPARING BRIVARACETAM AND INTERMEDIATE THEREOF ZHEJIANG HUAHAI PHARMACEUTICAL CO., LTD (CN) 2023-06-08 — — US disclosed
CN-114634437-B Simple preparation method of brivaracetam 武汉氟本氘合新材料科技有限公司 2023-05-30 — — CN disclosed
US-11518741-B2 Brivaracetam intermediate, preparation method therefor, and preparation method for brivaracetam SHANGHAI PUYI CHEMICAL CO., LTD. (CN) 2022-12-06 — — US disclosed
WO-2016191435-A1 PROCESSES TO PRODUCE BRIVARACETAM WANG PENG (US) 2016-12-01 — — WO disclosed
US-8338621-B2 Process for the preparation of 2-oxo-1-pyrrolidine derivatives UCB S.A. (BE) 2012-12-25 — — US disclosed
US-8338621-B2 Process for the preparation of 2-oxo-1-pyrrolidine derivatives UCB S.A. (BE) 2012-12-25 — — US disclosed
US-8338621-B2 Process for the preparation of 2-oxo-1-pyrrolidine derivatives UCB S.A. (BE) 2012-12-25 — — US disclosed
EP-1806339-B1 Process for the preparation of 2-oxo-1-pyrrolidine derivatives UCB PHARMA SA (BE) 2011-08-17 — — EP disclosed
US-20080009638-A1 PROCESS FOR THE PREPARATION OF 2-OXO-1-PYRROLIDINE DERIVATIVES UCB S.A. (BE) 2008-01-10 — — US disclosed
US-20080009638-A1 PROCESS FOR THE PREPARATION OF 2-OXO-1-PYRROLIDINE DERIVATIVES UCB S.A. (BE) 2008-01-10 — — US disclosed
US-20080009638-A1 PROCESS FOR THE PREPARATION OF 2-OXO-1-PYRROLIDINE DERIVATIVES UCB S.A. (BE) 2008-01-10 — — US disclosed
EP-1806339-A1 Process for the preparation of 2-oxo-1-pyrrolidine derivatives UCB, S.A. (BE) 2007-07-11 — — EP disclosed
EP-1806339-A1 Process for the preparation of 2-oxo-1-pyrrolidine derivatives UCB, S.A. (BE) 2007-07-11 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11673862-B2 Processes to produce brivaracetam BLVRB, CYP3A4, POR BRD4 157/4885MAPT 1149/4885MME 3613/4885
US-20080009638-A1 PROCESS FOR THE PREPARATION OF 2-OXO-1-PYRROLIDINE DERIVATIVES CYP2F1, CYP3A5, SULT1E1 BRD4 631/4885MAPT 1791/4885MME 4138/4885
US-11518741-B2 Brivaracetam intermediate, preparation method therefor, and preparation method for brivaracetam CYP51A1, FAR1, POR BRD4 1355/4885MAPT 4523/4885MME 4371/4885
US-20230373914-A1 PROCESS FOR THE PREPARATION OF (R)-4-PROPYL PYRROLIDINE-2-ONE, A KEY INTERMEDIATE FOR SYNTHESIS OF BRIVARACETAM BPGM, MGAM, HPD BRD4 452/4885MAPT 3064/4885MME 1162/4885
US-20230174478-A1 METHOD FOR PREPARING BRIVARACETAM AND INTERMEDIATE THEREOF BLVRB, GABBR2, CCKBR BRD4 306/4885MAPT 4126/4885MME 3292/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.